Glucocorticoid regulates parkin expression in mouse frontal cortex

Implications in schizophrenia

Chirayukumar D Pandya, Amanda Crider, Anilkumar R Pillai

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Stress and glucocorticoid hormones, which are released into the circulation following stressful experiences, have been shown to contribute significantly to the manifestation of various psychiatric illnesses including schizophrenia and depression. Studies in rodents have reported dose and time dependent effects of glucocorticoids on the expression of proteins related to neuroplasticity. However, the mechanism(s) involved in the regulation of proteins by glucocorticoids are not clear. Ubiquitin ligases play important role in degradation, trafficking and stabilization of proteins. The present study investigated the effect of glucocorticoid on ubiquitin-proteasome system in mouse frontal cortex. A significant increase in mRNA and protein levels of parkin, an E3 ubiquitin ligase was found in cultured mouse primary cortical neurons following corticosterone treatment. An increase in parkin levels was also found in mouse frontal cortex in vivo following acute dexamethasone treatment. However, chronic treatment with corticosterone did not change parkin protein levels in mouse frontal cortex. Studies using postmortem brain samples from schizophrenia and control subjects indicated a significant increase in parkin protein levels in frontal cortex of schizophrenia subjects suggesting a response to increased stress conditions in schizophrenia. These findings suggest a possible role of parkin in the pathophysiology of stress-related psychiatric disorders.

Original languageEnglish (US)
Pages (from-to)100-107
Number of pages8
JournalCurrent Neuropharmacology
Volume12
Issue number2
DOIs
StatePublished - Jan 1 2014

Fingerprint

Frontal Lobe
Glucocorticoids
Schizophrenia
Corticosterone
Ubiquitin
Psychiatry
Neuronal Plasticity
Ubiquitin-Protein Ligases
Protein Transport
Proteasome Endopeptidase Complex
Ligases
Dexamethasone
Rodentia
Proteins
Hormones
Depression
Neurons
Messenger RNA
Brain
parkin protein

Keywords

  • Cortex
  • Glucocorticoid
  • Neurons
  • Parkin
  • Schizophrenia

ASJC Scopus subject areas

  • Pharmacology
  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Glucocorticoid regulates parkin expression in mouse frontal cortex : Implications in schizophrenia. / Pandya, Chirayukumar D; Crider, Amanda; Pillai, Anilkumar R.

In: Current Neuropharmacology, Vol. 12, No. 2, 01.01.2014, p. 100-107.

Research output: Contribution to journalArticle

@article{3f42a3b6a7bf4a8dbb34ded106c61770,
title = "Glucocorticoid regulates parkin expression in mouse frontal cortex: Implications in schizophrenia",
abstract = "Stress and glucocorticoid hormones, which are released into the circulation following stressful experiences, have been shown to contribute significantly to the manifestation of various psychiatric illnesses including schizophrenia and depression. Studies in rodents have reported dose and time dependent effects of glucocorticoids on the expression of proteins related to neuroplasticity. However, the mechanism(s) involved in the regulation of proteins by glucocorticoids are not clear. Ubiquitin ligases play important role in degradation, trafficking and stabilization of proteins. The present study investigated the effect of glucocorticoid on ubiquitin-proteasome system in mouse frontal cortex. A significant increase in mRNA and protein levels of parkin, an E3 ubiquitin ligase was found in cultured mouse primary cortical neurons following corticosterone treatment. An increase in parkin levels was also found in mouse frontal cortex in vivo following acute dexamethasone treatment. However, chronic treatment with corticosterone did not change parkin protein levels in mouse frontal cortex. Studies using postmortem brain samples from schizophrenia and control subjects indicated a significant increase in parkin protein levels in frontal cortex of schizophrenia subjects suggesting a response to increased stress conditions in schizophrenia. These findings suggest a possible role of parkin in the pathophysiology of stress-related psychiatric disorders.",
keywords = "Cortex, Glucocorticoid, Neurons, Parkin, Schizophrenia",
author = "Pandya, {Chirayukumar D} and Amanda Crider and Pillai, {Anilkumar R}",
year = "2014",
month = "1",
day = "1",
doi = "10.2174/1570159X11666131120224950",
language = "English (US)",
volume = "12",
pages = "100--107",
journal = "Current Neuropharmacology",
issn = "1570-159X",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Glucocorticoid regulates parkin expression in mouse frontal cortex

T2 - Implications in schizophrenia

AU - Pandya, Chirayukumar D

AU - Crider, Amanda

AU - Pillai, Anilkumar R

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Stress and glucocorticoid hormones, which are released into the circulation following stressful experiences, have been shown to contribute significantly to the manifestation of various psychiatric illnesses including schizophrenia and depression. Studies in rodents have reported dose and time dependent effects of glucocorticoids on the expression of proteins related to neuroplasticity. However, the mechanism(s) involved in the regulation of proteins by glucocorticoids are not clear. Ubiquitin ligases play important role in degradation, trafficking and stabilization of proteins. The present study investigated the effect of glucocorticoid on ubiquitin-proteasome system in mouse frontal cortex. A significant increase in mRNA and protein levels of parkin, an E3 ubiquitin ligase was found in cultured mouse primary cortical neurons following corticosterone treatment. An increase in parkin levels was also found in mouse frontal cortex in vivo following acute dexamethasone treatment. However, chronic treatment with corticosterone did not change parkin protein levels in mouse frontal cortex. Studies using postmortem brain samples from schizophrenia and control subjects indicated a significant increase in parkin protein levels in frontal cortex of schizophrenia subjects suggesting a response to increased stress conditions in schizophrenia. These findings suggest a possible role of parkin in the pathophysiology of stress-related psychiatric disorders.

AB - Stress and glucocorticoid hormones, which are released into the circulation following stressful experiences, have been shown to contribute significantly to the manifestation of various psychiatric illnesses including schizophrenia and depression. Studies in rodents have reported dose and time dependent effects of glucocorticoids on the expression of proteins related to neuroplasticity. However, the mechanism(s) involved in the regulation of proteins by glucocorticoids are not clear. Ubiquitin ligases play important role in degradation, trafficking and stabilization of proteins. The present study investigated the effect of glucocorticoid on ubiquitin-proteasome system in mouse frontal cortex. A significant increase in mRNA and protein levels of parkin, an E3 ubiquitin ligase was found in cultured mouse primary cortical neurons following corticosterone treatment. An increase in parkin levels was also found in mouse frontal cortex in vivo following acute dexamethasone treatment. However, chronic treatment with corticosterone did not change parkin protein levels in mouse frontal cortex. Studies using postmortem brain samples from schizophrenia and control subjects indicated a significant increase in parkin protein levels in frontal cortex of schizophrenia subjects suggesting a response to increased stress conditions in schizophrenia. These findings suggest a possible role of parkin in the pathophysiology of stress-related psychiatric disorders.

KW - Cortex

KW - Glucocorticoid

KW - Neurons

KW - Parkin

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=84896332659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896332659&partnerID=8YFLogxK

U2 - 10.2174/1570159X11666131120224950

DO - 10.2174/1570159X11666131120224950

M3 - Article

VL - 12

SP - 100

EP - 107

JO - Current Neuropharmacology

JF - Current Neuropharmacology

SN - 1570-159X

IS - 2

ER -